BioMarin Pharma (BMRN) Tops Q4 EPS by 29c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.39 --0%
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
OMID, ACI, UNH, More
Revenue Growth %: +31.4%
Financial Fact:
NET INCOME (LOSS) PER SHARE, DILUTED: -0.26
Today's EPS Names:
OMID, ACI, UNH, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of $0.49, $0.29 better than the analyst estimate of $0.20. Revenue for the quarter came in at $646.2 million versus the consensus estimate of $639.26 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $2.60-$2.80, versus the consensus of $2.83. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.82 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Upgrades BioMarin Pharmaceutical Inc. (BMRN) to Strong Buy
- Mizuho Upgrades Rexford Industrial Realty (REXR) to Outperform
- Cryo-Cell International, Inc. (CCEL) Tops Q3 EPS by 13c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
